Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesLiabilities and Shareholders EquityOther Accumulated ExpensesPayablesReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CervoMed (CRVO) Other Accumulated Expenses (2022 - 2025)

Historic Other Accumulated Expenses for CervoMed (CRVO) over the last 9 years, with Q1 2025 value amounting to $2.1 million.

  • CervoMed's Other Accumulated Expenses rose 4780.81% to $2.1 million in Q1 2025 from the same period last year, while for Mar 2025 it was $2.1 million, marking a year-over-year increase of 4780.81%. This contributed to the annual value of $2.4 million for FY2024, which is 2247.82% up from last year.
  • Latest data reveals that CervoMed reported Other Accumulated Expenses of $2.1 million as of Q1 2025, which was up 4780.81% from $2.4 million recorded in Q4 2024.
  • Over the past 5 years, CervoMed's Other Accumulated Expenses peaked at $2.4 million during Q4 2024, and registered a low of $532550.0 during Q2 2023.
  • Moreover, its 4-year median value for Other Accumulated Expenses was $1.5 million (2022), whereas its average is $1.5 million.
  • Data for CervoMed's Other Accumulated Expenses shows a peak YoY increase of 20008.07% (in 2023) and a maximum YoY decrease of 6809.15% (in 2023) over the last 5 years.
  • CervoMed's Other Accumulated Expenses (Quarter) stood at $644252.0 in 2022, then surged by 200.08% to $1.9 million in 2023, then increased by 22.48% to $2.4 million in 2024, then dropped by 12.05% to $2.1 million in 2025.
  • Its Other Accumulated Expenses stands at $2.1 million for Q1 2025, versus $2.4 million for Q4 2024 and $2.2 million for Q3 2024.